Loading...
XKRX
030000
Market cap1.24bUSD
Apr 11, Last price  
17,420.00KRW
1D
-0.51%
1Q
1.28%
Jan 2017
10.60%
Name

Cheil Worldwide Inc

Chart & Performance

D1W1MN
P/E
8.50
P/S
0.41
EPS
2,048.97
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
4.89%
Revenues
4.34t
+4.98%
694,685,148,0001,173,496,790,0001,169,390,650,0001,344,516,085,0001,758,178,413,1502,365,019,210,8102,709,281,436,3802,666,255,721,5702,806,713,644,1603,232,593,889,3603,374,986,899,1803,477,880,993,8303,421,672,988,2302,747,921,881,0203,325,712,307,5204,253,367,260,0004,138,274,796,0304,344,256,680,950
Net income
207.52b
+10.79%
59,818,978,00086,691,935,00091,629,522,000103,467,820,00093,313,720,00093,651,708,00098,540,230,700101,604,521,74079,514,267,81088,263,165,590127,153,226,530129,712,696,670138,055,156,770157,399,949,860165,485,251,450193,731,654,300187,301,872,830207,516,530,910
CFO
346.40b
+29.88%
50,058,181,000196,384,008,00049,337,880,000-19,337,217,000144,587,874,39091,241,087,140-66,212,477,49055,909,773,950102,393,207,950101,351,735,63039,090,197,990224,014,016,080200,015,098,570219,474,826,500249,513,810,060184,163,142,560266,698,725,630346,397,436,400
Dividend
Dec 27, 20231110 KRW/sh
Earnings
Apr 24, 2025

Profile

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton, Australia.
URL
https://us.cheil.com/?languages=en®ionNm=USA
IPO date
Mar 03, 1998
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,344,256,681
4.98%
4,138,274,796
-2.71%
4,253,367,260
27.89%
Cost of revenue
2,892,903,871
2,827,398,812
2,984,296,646
Unusual Expense (Income)
NOPBT
1,451,352,810
1,310,875,984
1,269,070,614
NOPBT Margin
33.41%
31.68%
29.84%
Operating Taxes
105,152,878
94,701,074
104,600,606
Tax Rate
7.25%
7.22%
8.24%
NOPAT
1,346,199,932
1,216,174,910
1,164,470,008
Net income
207,516,531
10.79%
187,301,873
-3.32%
193,731,654
17.07%
Dividends
(112,748,950)
(117,410,333)
(100,265,938)
Dividend yield
6.09%
4.30%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
47,274,211
55,280,888
71,370,025
Long-term debt
261,960,755
290,137,344
307,683,710
Deferred revenue
20,098,941
380,000
Other long-term liabilities
76,316,697
99,279,190
34,556,353
Net debt
(503,487,615)
(425,400,610)
(258,856,367)
Cash flow
Cash from operating activities
346,397,436
266,698,726
184,163,143
CAPEX
(26,371,189)
(26,189,270)
(22,290,308)
Cash from investing activities
(78,497,500)
(7,489,351)
16,405,679
Cash from financing activities
(170,328,909)
(192,340,326)
(163,263,010)
FCF
1,303,746,146
1,120,876,779
1,070,245,460
Balance
Cash
849,562,319
690,966,380
632,251,961
Long term investments
(36,839,738)
79,852,462
5,658,142
Excess cash
595,509,747
563,905,102
425,241,740
Stockholders' equity
1,626,186,559
1,456,629,701
2,145,796,185
Invested Capital
1,115,614,692
1,005,846,960
962,806,610
ROIC
126.91%
123.55%
125.95%
ROCE
81.13%
83.51%
89.22%
EV
Common stock shares outstanding
101,279
101,279
Price
16,950.00
-10.93%
19,030.00
-17.44%
23,050.00
0.88%
Market cap
1,927,334,137
-17.44%
2,334,474,611
0.88%
EV
1,513,139,096
2,085,006,166
EBITDA
1,528,386,043
1,385,858,957
1,342,605,149
EV/EBITDA
1.09
1.55
Interest
9,819,844
10,904,483
6,925,018
Interest/NOPBT
0.68%
0.83%
0.55%